Browsing by Subject "Immunotherapy"
Now showing items 1-20 of 37
-
A Natural Impact: NK Cells at the Intersection of Cancer and HIV Disease.
(Frontiers in immunology, 2019-01)Despite efficient suppression of plasma viremia in people living with HIV (PLWH) on cART, evidence of HIV-induced immunosuppression remains, and normally benign and opportunistic pathogens become major sources of co-morbidities, ... -
Antibody-mediated Immunotherapy of Brain Tumors
(2017)Conventional therapy for malignant glioma (MG) fails to specifically target tumor cells. In contrast, immunotherapy offers an exquisitely precise approach, and substantial evidence indicates that if appropriately redirected, ... -
Antineoplastic Cytotoxicity and Immune Adjuvancy of a Recombinant Oncolytic Poliovirus
(2016)Our group has pioneered the development of a live-attenuated poliovirus, called PVSRIPO, for the purpose of targeting cancer. Despite clinical progress, the cancer selective cytotoxicity and immunotherapeutic potential of ... -
Bench to bedside: A Bispecific Antibody for treating Brain Tumors
(2019)Malignant gliomas are the most common primary brain tumor in adults, with an incidence of five cases per 100,000 persons per year. Grade IV glioblastoma is the most aggressive form and prognosis remains poor despite the ... -
CAR T-cell Immunotherapy for Brain Tumors
(2017)Glioblastoma (GBM) is the most common and deadly primary malignant brain tumor. Despite an aggressive multimodal standard of care, prognoses and patient quality of life remain exceptionally poor, due in part to the non-specific ... -
Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma.
(Journal for immunotherapy of cancer, 2018-01-29)Nivolumab is approved for patients with metastatic renal cell carcinoma (mRCC) refractory to prior antiangiogenic therapy. The clinical activity of nivolumab in patients with non-clear cell RCC subtypes remains unknown as ... -
Designing a Low-Cost Cancer Therapeutic with Ethanol Ablation and Immunomodulation
(2021)Breast cancer outcomes globally are dependent on access to advanced operating room technology and radiation therapy facilities. In low-income countries, 90% of patients cannot access either radiation or surgery due to a ... -
Detection of amino-terminal extracellular domain of somatostatin receptor 2 by specific monoclonal antibodies and quantification of receptor density in medulloblastoma.
(Hybridoma (Larchmt), 2009-12)Somatostatin receptor 2 (SSTR2) is expressed by most medulloblastomas (MEDs). We isolated monoclonal antibodies (MAbs) to the 12-mer (33)QTEPYYDLTSNA(44), which resides in the extracellular domain of the SSTR2 amino terminus, ... -
Development of Delivery Strategies Facilitating Broad Application of Messenger RNA Tumor Vaccine
(2014)Genetic modification of dendritic cells with plasmid DNA is plagued with low transfection efficiencies because DNA taken up by non-dividing dendritic cells rarely reaches the nucleus. But this difficulty can be overcome ... -
Dissecting Mechanisms of Tumor Response and Resistance to Radiation and Immunotherapy
(2020)Over half of all cancer patients receive radiation therapy, and it contributes to over 40% of cancer cures. Within the last decade, cancer immunotherapy has become a pillar of cancer therapy, along with surgery, chemotherapy, ... -
EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma.
(PLoS One, 2014)Glioblastoma (GBM) is the most common primary malignant brain tumor in adults and is uniformly lethal. T-cell-based immunotherapy offers a promising platform for treatment given its potential to specifically target tumor ... -
Expanding anti-CD38 immunotherapy for lymphoid malignancies.
(Journal of experimental & clinical cancer research : CR, 2022-06-28)<h4>Background</h4>Lymphoid neoplasms, including multiple myeloma (MM), non-Hodgkin lymphoma (NHL), and NK/T cell neoplasms, are a major cause of blood cancer morbidity and mortality. CD38 (cyclic ADP ribose hydrolase) is ... -
Identification of a Germline Pyrin Variant in a Metastatic Melanoma Patient With Multiple Spontaneous Regressions and Immune-related Adverse Events.
(Journal of immunotherapy (Hagerstown, Md. : 1997), 2022-07)The mechanisms underlying tumor immunosurveillance and their association with the immune-related adverse events (irAEs) associated with checkpoint inhibitor immunotherapies remain poorly understood. We describe a metastatic ... -
Improving Anticancer Therapy with ELP-based Drug Delivery Systems
(2016)Cytotoxic chemotherapy is a mainstay of cancer treatment, administered to patients who require systemic treatment based on the stage of their disease. Due to its dose-limiting side-effects, chemotherapy is commonly administered ... -
Investigating Cognitive/Affective/Sleep disturbance symptoms in Patients Receiving High-Dose Interleukin-2 Therapy
(2018)Patients undergoing intensive treatments for life-limiting chronic illnesses such as cancer often experience severe cognitive, affective, and sleep disturbance symptoms. Immunotherapies such as high-dose Interleukin-2 (IL-2) ... -
Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review.
(J Immunother Cancer, 2015)BACKGROUND: Ipilimumab improves survival in metastatic melanoma patients. This population frequently develops brain metastases, which have been associated with poor survival and are often treated with radiation. Therefore, ... -
Melanoma-Derived Wnt5a Promotes Local Dendritic-Cell Expression of IDO and Immunotolerance: Opportunities for Pharmacologic Enhancement of Immunotherapy.
(Cancer Immunol Res, 2015-09)The β-catenin signaling pathway has been demonstrated to promote the development of a tolerogenic dendritic cell (DC) population capable of driving regulatory T-cell (Treg) differentiation. Further studies have implicated ... -
Membrane GRP78: Pathologic and Therapeutic Roles in Ovarian Cancer
(2014)Ovarian cancer is the fifth leading cause of cancer-related death in the United States and the most lethal gynecologic malignancy. Patients with ovarian cancer are generally diagnosed at stage III or IV, when ascites fluid ... -
MRP3: a molecular target for human glioblastoma multiforme immunotherapy.
(BMC Cancer, 2010-09-01)BACKGROUND: Glioblastoma multiforme (GBM) is refractory to conventional therapies. To overcome the problem of heterogeneity, more brain tumor markers are required for prognosis and targeted therapy. We have identified and ... -
Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice.
(PLoS One, 2013)Temozolomide (TMZ) is an alkylating agent shown to prolong survival in patients with high grade glioma and is routinely used to treat melanoma brain metastases. A prominent side effect of TMZ is induction of profound lymphopenia, ...
